tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Hemogenyx Pharmaceuticals Advances CAR-T Therapy Trials and Eyes Early Revenue

Story Highlights
  • Hemogenyx Pharmaceuticals progresses HG-CT-1 trials with successful patient treatments.
  • Company secures partnerships and regulatory clearance for potential early revenue in Europe.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Hemogenyx Pharmaceuticals Advances CAR-T Therapy Trials and Eyes Early Revenue

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ) just unveiled an announcement.

Hemogenyx Pharmaceuticals has announced significant progress in its clinical trials for HG-CT-1, a CAR-T cell therapy for R/R AML, with three patients successfully treated and early signs of efficacy observed. The company has also secured regulatory clearance for pediatric trial expansion and entered a strategic manufacturing partnership, positioning it for potential early revenue generation in Europe through a collaboration with Cellin Technologies.

More about HemoGenyx Pharmaceuticals Plc

Hemogenyx Pharmaceuticals Plc is a biopharmaceutical company focused on developing transformative therapies for blood diseases, particularly targeting relapsed or refractory acute myeloid leukemia (R/R AML) with its FLT3-targeted autologous CAR-T cell therapy, HG-CT-1.

Average Trading Volume: 128,713

Technical Sentiment Signal: Strong Buy

Current Market Cap: £58.97M

See more insights into HEMO stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1